ARTÍCULOS ORIGINALES
Efecto hepatoprotector de la mezcla de ácido ursólico/ácido oleanólico en ratones con daño hepático inducido con fármacos antituberculosos
Hepatoprotective effect of the ursolic acid-oleanolic acid mixture in mice with liver damage induced with anti-TB drugs
Volumen 9, Número 1
2025
e090102
Alicia Georgina Siordia-Reyes (1), Roberto Joaquín Robles-Ramírez (2), María Adelina Jiménez-Arellanes (3).
Afiliaciones:
1. Anatomía Patológica, UMAE Hospital de Pediatría “Dr. Silvestre Frenk Freund”, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México.
2. División Auxiliar de Diagnóstico y Tratamiento, UMAE Hospital de Pediatría “Dr. Silvestre Frenk Freund”, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México.
3. Unidad de Investigación Médica en Farmacología, UMAE Hospital de Especialidades “Dr. Bernardo Sepúlveda Gutiérrez”, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México.
Correspondencia:
María Adelina Jiménez-Arellanes: adelinajim08@prodigy.net.mx
2025 © Siordia-Reyes AG, Robles-Ramírez RJ, Jiménez-Arellanes MA. Efecto hepatoprotector de la mezcla de ácido ursólico/ácido oleanólico en ratones con daño hepático inducido con fármacos antituberculosos.
Esta obra se distribuye bajo una Licencia Creative Commons Reconocimiento-NoComercial 4.0 Internacional (CC BY-NC).
Los autores declararon que no tienen conflictos de intereses.
Este trabajo se desarrolló con el financiamiento del proyecto FIS/IMSS/PROT/G16/ 1577 (CLIC: R-2015-3601-47).
Sugerencia de cita:
Siordia-Reyes AG, Robles-Ramírez RJ, Jiménez-Arellanes MA. Efecto hepatoprotector de la mezcla de ácido ursólico/ácido oleanólico en ratones con daño hepático inducido con fármacos antituberculosos. Rev Cadena Cereb. 2025; 9(1): e090102.
Recibido: 19 de febrero de 2025
Aceptado: 6 de marzo de 2025
RESUMEN
Objetivo: Evaluar el efecto hepatoprotector (HPP) de la mezcla ácido ursólico-ácido oleanólico (AU/AO) administrado por vía intragástrica (i.g.) ante el daño provocado por fármacos antituberculosos (rifampicina/isoniazida/pirazinamida, -RIF/INH/PZA-).
Materiales y métodos: La mezcla de AU/AO se obtuvo a partir del extracto metanólico (MeOH) de Rosmarinus officinalis. El ensayo se realizó en ratones machos Balb/C con daño hepático inducido con RIF/INH/PZA y como control positivo se empleó silimarina (SIL). La mezcla AU/AO se administró por via intragástrica (i.g.) a 10 y 20 mg/kg durante 60 días.
Resultados: La mezcla AU/AO a 10 y 20 mg/kg administrado durante 60 días favoreció la ganancia de peso y disminuyó los valores de aspartato aminotransferasa (AST), alanina aminotransferasa (ALT) y fosfatasa alcalina (FA). Este efecto fue similar al del control positivo SIL. A nivel histológico se observó ligera disminución de esteatosis en el grupo que recibió la mezcla de AU/AO a 10 mg/kg, respecto al grupo con daño hepático y con respecto al grupo de AU/AO a 20 mg/kg. La mezcla de AU/AO a 10 mg/kg mostró buen efecto HPP.
Conclusiones: La mezcla de AU/AO administrado por via i.g. favoreció la ganancia de peso corporal (GPC), y disminuyo los valores de enzimas hepáticas, también redujo la esteatosis ante el daño inducido por fármacos antituberculosos. La mejor dosis fue la de 10 mg/kg administrado durante 60 días.
Palabras Clave:
ácido oleanólico; ácido ursólico; triterpenos; hepatoptotector; antituberculosos; silimarina.
ABSTRACT
Objective: To evaluate the hepatoprotective effect (HPP) of the ursolic acid-oleanolic acid (UA/OA) mixture administered intragastrically (i.g.) against damage induced by antituberculosis drugs (rifampicin/isoniazid/pyrazinamide, -RIF/INH/PZA-).
Materials and methods: The UA/OA mixture was obtained from the methanolic extract (MeOH) of Rosmarinus officinalis. The assay was performed in male Balb/C mice with RIF/INH/PZA-induced liver damage, and silymarin (SIL) was used as a positive control. The UA/OA mixture was administered intragastrically (i.g.) at 10 and 20 mg/kg for 60 days.
Results: The UA/AO mixture at 10 and 20 mg/kg administered for 60 days promoted weight gain and decreased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (AP) levels. This effect was similar to that of the positive control SIL. Histologically, a slight decrease in steatosis was observed in the group receiving the UA/AO mixture at 10 mg/kg, compared to the group with liver damage and compared to the UA/AO group at 20 mg/kg. The UA/AO mixture at 10 mg/kg showed a positive HPP effect.
Conclusions: The UA/AO mixture administered i.g. promoted body weight gain (BWG) and decreased liver enzyme levels. It also reduced steatosis in the context of damage induced by antituberculosis drugs. The optimal dose was 10 mg/kg administered for 60 days.
Keywords:
Oleanolic acid; ursolic acid; triterpenes; hepato-protective; antitubercular; silymarin.
REFERENCIAS
1. Silva DR, Mello FCQ, Migliori GB. Tuberculosis series 2020. J Bras Pneumol. 2020; 46(2): e20200027. DOI: 10.36416/1806-3756/e20200027
2. World Health Organization [internet]. Geneva: World Health Organization. Global tuberculosis report 2019. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
3. World Health [internet]. Geneva: World Health Organization. Global tuberculosis report 2020. Disponible en: https://www.who.int/publications/i/item/9789240013131
4. Brigden G, Nyang’wa BT, du Cros P, Francis V, Jennifer H, Rich M, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014; 92(1):68-74. DOI: 10.2471/BLT.13.122028
5. Günther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med (Lond). 2014; 14(3): 279-285. DOI: 10.7861/clinmedicine.14-3-279
6. Njoku DB. Drug-induced hepatotoxicity: Metabolic, genetic and immunological basis. Int J Mol Sci. 2014; 15(4): 6990-7003. DOI: 10.3390/ijms15046990
7. Pérez-González MZ, Siordia-Reyes AG, Damián-Nava P, Hernández-Ortega S, Macías-Rubalcava ML, Jiménez-Arellanes MA. Hepatoprotective and Anti-Inflammatory Activities of the Cnidoscolus chayamansa (Mc Vaugh) Leaf Extract in Chronic Models. Evid Based Complement Alternat Med. 2018 (2018): 3896517. DOI: 10.1155/2018/3896517
8. Pérez-González MZ, Macías-Rubalcava ML, Hernández-Ortega S, Siordia-Reyes G, Jiménez-Arellanes MA. Additional compounds and the therapeutic potential of Cnidoscolus chayamansa (McVaugh) against hepatotoxicity induced by antituber-cular drugs. Biomed Pharmacother. 2019; 117:109140. DOI: 10.1016/j.biopha.2019.109140
9. Ramírez-Marroquín OA, Jiménez-Arellanes MA. Hepato-protective effect from natural compounds, biological products and medicinal plant extracts on antitu-bercular drug-induced liver injuries: A systematic review. Med Aromat Plants. 2019; 8: 339(1-12). DOI: 10.35248/2167- 0412.19.8.339
10. Jiménez-Arellanes MA, Gutiérrez-Rebolledo GA, Meckes-Fischer M, León-Díaz R. Medical plant extracts and natural compounds with a hepatoprotective effect against damage caused by antitubercular drugs: A review. Asian Pac J Trop Med. 2016; 9(12): 1141-1149. DOI: 10.1016/j.apjtm.2016.10.010
11. Nagarajan S, Whitaker P. Management of adverse reactions to first-line tubercu-losis antibiotics. Curr Opin Allergy Clinical Immunol. 2018; 18(4):333-341. DOI: 10.1097/ACI.0000000000000462
12. Metushi I, Uetrecht J, Phillips E. Mechanism of Isonizid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016; 81:1030-1036. DOI: 10.1111/bcp.12885
13. Mukherjee A, Lodha R, Kabra SK. Pharmacokinetics of First-Line Anti-Tubercular Drugs. Indian J Pediatr 2019; 86(5):468-478. DOI: 10.1007/s12098-019-02911-w
14. Perwitasari DA, Irham LM, Darmawan E, Mulyani UA, Atthobari J. CYP2E1 poly-morphism, acetylator profiles and drug-induced liver injury incidence of Indone-sian tuberculosis patients. Indian J Tuberc. 2016; 63(3):139-143. DOI: 10.1016/j.ijtb.2016.08.001
15. Suvichapanich S, Fukunaga K, Zahroh H, Mushiroda T, Mahasirimongkol S, Toyo-Oka L, et al. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. Pharmacogenet Genomics. 2018; 28(7): 167-176. DOI: 10.1097/FPC.0000000000000339
16. Abe F, Yamauchi T, Nagao T, Kinjo J, Okabe H, Higo H, et al. Ursolic acid as a trypanocidal constituent in rosemary. Biol Pharm Bull. 2002; 25(11):1485-1487. DOI: 10.1248/bpb.25.1485
17. Lukaczer D, Darland G, Tripp M, Liska DA, Lerman RH, Schiltz B, et al. A Pilot trial evaluating meta050, a proprietary combination of reduced iso‐alpha acids, rose-mary extract and oleanolic acid in patients with arthritis and fibromyalgia. Phytot-her Res. 2005; 19(10):864-869. DOI: 10.1002/ptr.17
18. Martínez AL, González-Trujano ME, Chávez M, Pellicer F. Antinociceptive effecti-veness of triterpenes from rosemary in visceral nociception. J Ethnopharmacol. 2012; 142(1):28-34. DOI: 10.1016/j.jep.2012.03.052
19. Beltrán-Villalobos KL, Déciga-Campos M, Aguilar-Mariscal H, González-Trujano ME, Martínez-Salazar MF, Ramírez-Cisneros MA, et al. Synergistic antinociceptive interaction of Syzygium aromaticum or Rosmarinus officinalis coadministered with ketorolac in rats. Biomed Pharmacother. 2017; 94: 858-864. DOI: 10.1016/j.biopha.2017.07.166
20. Jiménez-Arellanes A, Luna-Herrera J, Cornejo J, López-García S, Castro-Mussot ME, Meckes-Fischer M, et al. Ursolic and oleanolic acids as antimicrobial and immunomodulatory compounds for tuberculosis treatment. BMC Complement Alter Med. 2013; 13(1): 258-269. DOI: 10.1186/1472-6882-13-258
21. Gutiérrez-Rebolledo GA, Siordia-Reyes GA, Meckes-Fischer M, Jiménez-Arellanes A. Hepatoprotective properties of oleanolic and ursolic acids in anti-tubercular drug-induced liver damage. Asian Pac Trop Med. 2016; 9(7): 644-651. DOI: 10.1016/j.apjtm.2016.05.015
22. Seebacher W, Simic N, Weis R, Saf R, Kunert O. Spectral Assignments and refe-rence data. Complete assignments of 1H and 13C NMR resonances of oleanolic acid, 18αα-oleanolic acid, ursolic acid and their 11-oxo derivatives. Magn Reson Chem. 2003; 41(8): 636-638. DOI: 10.1002/mrc.1214
23. Sakashita K, Murata K, Takahashi Y, Yamamoto M, Oohashi K, Sato Y, et al. A Case Series of Acute Kidney Injury During Anti-tuberculosis Treatment. Intern Med. 2019; 58(4): 521-527. DOI: 10.2169/internalmedicine.0813-18
24. Siordia-Reyes GA, Cornejo-Garrido Jorge, Jiménez-Arellanes MA. Nephro- and Hepatoprotective effect of Rosmarinus officinalis against damage induced with anti-tb drugs in chronic model. Pharmacogn J. 2021; 13(3): 722-729. DOI: 10.5530/pj.2021.13.92
25. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: Mecha-nisms and management. J Clin Exp Hepatol. 2013; 3(1):37-49. DOI: 10.1016/j.jceh.2012.12.001
26. Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, So-bhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Alter Med. 2015; 15: 334. DOI: 10.1186/s12906-015-0861-7
27. Eminzade S, Uraz F, Izzettin FV. Silymarinprotects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab (Lond). 2008; 5(18): 1-8. DOI: 10.1186/1743-7075-5-18
28. Rodríguez-Flores EM, Mata-Espinosa D, Barrios-Payan J, Marquina-Castillo B, Castañón-Arreola M, Hernández-Pando R. A significant therapeutic effect of silymarin administered alone, or in combination with chemotherapy, in experi-mental pulmonary tuberculosis caused by drug-sensitive or drug-resistant strains: in vitro and in vivo studies. PLoS One. 2019: 14(5):e0217457. DOI: 10.1371/journal.pone.0217457
29. Jiménez-Arellanes MA. Silimarina como potencial agente hepatoprotector. Rev Cadena Cereb. 2019, 3(2): 60-70. Disponible en: https://www.cadenadecerebros.com/art-re-32-02
30. Nicoletti NF, Rodrigues-Junior V, Santos Jr AA, Leite CE, Dias ACO, Batista Jr EL, et al. Protective effects of resveratrol on hepatotoxicity induced by isoniazid and rifampicin via SIRT1 modulation. J Nat Prod. 2014; 77(10): 2190-2195. DOI: 10.1021/np5003143
31. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González Á, Esquivel-Soto J, Esquivel-Chirino C, García-Luna M, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014; 6(3): 144-149. DOI: 10.4254/wjh.v6.i3.144
32. Girish C, Pradhan SC. Drug development for liver diseases: focus on picroliv, ellagic acid and curcumin. Fundam Clin Pharmacol. 2008; 22(6): 623-663. DOI: 10.1111/j.1472-8206.2008.00618.x
33. Jiménez-Arellanes MA, Franco-García M, Léon-Díaz R. Current Status of Mexican Medicinal Plants as Source of Antimycobacterial and Antituberculosis Com-pounds. J Infect Dis Ther. 2019; 7(6): 1000414; 1-4. Disponible en: https://www.omicsonline.org/open-access/current-status-from-mexican-medicinal-plants-as-source-of-antimycobacterial-and-antituberculosis-compounds.pdf
34. Cornejo-Garrido J, Chamorro-Cevallos GA, Garduño-Siciliano L, Hernández-Pando R, Jiménez-Arellanes MA. Acute and subacute toxicity (28 days) of a mixture of ursolic acid and oleanolic acid obtained from Bouvardia ternifolia in mice. Bol Latinoam Caribe Plant Med Aromats. 2012; 11(1):91-102. Disponible en: https://www.redalyc.org/articulo.oa?id=85622229011
35. do Nascimento PG, Lemos TL, Bizerra AM, Arriaga AM, Ferreira DA, Santiago GM, et al. Antibacterial and Antioxidant Activities of Ursolic Acid and Derivates. Molecules 2014; 19: 1317-1327. DOI: 10.3390/molecules19011317
36. Ayeleso TB, Matumba MG, Mukwevho E. Oleanolic Acid and Its Derivates: Biolo-gical Activities and Therapeutic Potential in Chronic Diseases. Molecules. 2017; 22(11): 1915. DOI: 10.3390/molecules22111915